A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes

Published:2013-03-04 Issue:8 Volume:15 Page:721-728
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Ferrannini E.¹,Seman L.²,Seewaldt-Becker E.³,Hantel S.³,Pinnetti S.³,Woerle H. J.⁴

Affiliation:

1. Department of Internal Medicine; University of Pisa; Pisa; Italy

2. Boehringer Ingelheim Pharmaceuticals, Inc.; Ridgefield; CT; USA

3. Boehringer Ingelheim Pharma GmbH & Co. KG; Biberach; Germany

4. Boehringer Ingelheim Pharma GmbH & Co. KG; Ingelheim; Germany

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12081/fullpdf

Reference16 articles.

1. Prevention and early detection of vascular complications of diabetes;Marshall;BMJ,2006

2. Treatment approach and HbA1c control among US adults with type 2 diabetes: NHANES 1999-2004;Dodd;Curr Med Res Opin,2009

3. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects;Ferrannini;Nat Rev Endocrinol,2012

4. Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes;Chao;Core Evid,2012

5. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabete;Rosenstock;Diabetes Care,2012

Cited by 166 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fluid Restriction for Patients with Heart Failure: Current Evidence and Future Perspectives;Journal of Personalized Medicine;2024-07-11

2. Effects of Empagliflozin‐Induced Glycosuria on Weight Gain, Food Intake and Metabolic Indicators in Mice Fed a High‐Fat Diet;Endocrinology, Diabetes & Metabolism;2024-03

3. Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension;Diabetes & Metabolism Journal;2023-11-30

4. Comparative safety of different recommended doses of sodium–glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials;Frontiers in Endocrinology;2023-11-10

5. A Comparison of Efficacy among Syrian diabetic patients treated with Empagliflozin versus Dapagliflozin, a Randomized, Triple-blind, Two-period crossover study;Research Journal of Pharmacy and Technology;2023-10-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3